ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

ClinicalTrials.gov ID: NCT06520098

Public ClinicalTrials.gov record NCT06520098. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Study identification

NCT ID
NCT06520098
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
VA Office of Research and Development
Federal
Enrollment
100 participants

Conditions and interventions

Interventions

  • Ibrutinib, Acalabrutinib, Zanubrutinib Drug
  • Venetoclax Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2025
Primary completion
Jun 29, 2030
Completion
Dec 30, 2030
Last update posted
Oct 13, 2025

2025 – 2030

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
San Francisco VA Medical Center, San Francisco, CA San Francisco California 94121-1563 Recruiting
Kansas City VA Medical Center, Kansas City, MO Kansas City Missouri 64128-2226 Recruiting
Durham VA Medical Center, Durham, NC Durham North Carolina 27705-3875 Recruiting
VA Puget Sound Health Care System Seattle Division, Seattle, WA Seattle Washington 98108-1532 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06520098, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2025 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06520098 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →